The retrospective evaluation of prophylactic cranial irradiation in patients treated for limited stage small-cell lung cancer — a single centre study by Sas-Korczyńska, Beata et al.
280
Artykuł oryginalny
Biuletyn Polskiego 
Towarzystwa Onkologicznego 
NOWOTWORY
2018, tom 3, nr 5–6, 280–287
© Polskie Towarzystwo Onkologiczne
ISSN 2543–5248
www.nowotwory.edu.pl
1Clinic of Oncology and Department of Radiotherapy, Maria Skłodowska-Curie Institute — Oncology Center, Kraków 
Branch, Poland
2Department of Ophthalmology, Collegium Medicum Jagiellonian University, Kraków, Poland 
3Deparment of Diagnostic Radiology, Maria Skłodowska-Curie Institute — Oncology Center, Kraków Branch, Poland
4Department of Statistics, University of Economics, Kraków, Poland
The retrospective evaluation of prophylactic cranial irradiation in 
patients treated for limited stage small-cell lung cancer  
— a single centre study
Beata Sas-Korczyńska1, 2, Elżbieta Łuczyńska3, Adrianna Chudyba1, Tomasz Skóra1,  
Andrzej Sokołowski4
Introduction . The standard treatment for patients with LD SCLC (limited stage small-cell lung cancer) is combined 
modality therapy that includes chemotherapy (ChT) with platinum-based regimens and thoracic radiotherapy (RT), 
followed by prophylactic cranial irradiation (PCI) in patients with a response in the thorax.
Objectives . The evaluation of PCI in patients with LD SCLC and the analysis of the effects of certain therapeutic factors 
on the frequency and occurrence of brain metastases.
Materials and methods . Between 2002 and 2015, a total of 271 patients with LD SCLC received chemo-radiotherapy 
(concurrently in 122 pts — 45% and sequential in 149 pts — 55%). PCI was administered in 167 pts (61.6%) with total 
dose of 30 Gy given to the whole brain; 86 pts (51.1%) received PCI after completed chemo-radiotherapy and in 81 
pts (48.9%) PCI was administered immediately after the end of thoracic irradiation. 
The following statistical methods were used: Kaplan-Meier method (evaluation of survival rates: overall survival — 
OS, and brain metastases-free survival — BMFS), log-rank test (for comparison of survival rates), Cox’ proportional 
hazard model (for multivariate analysis), Pearson chi2 test for independence (for categorized variables comparison) 
and variance analysis (for continuous variables comparison). All the calculations were performed using Statistica v. 
13.3 software (TIBCO Software Inc.) and the significance level for all the statistical methods was p < 0.05.
Results . Complete response in thorax was observed in 172 pts (63.5%) and remaining 99 pts (36.5%) developed partial 
response. During follow-up, 120 pts (44.3%) developed distant metastases from which brain metastases were most 
frequent (61 cases — 60.8%). The cumulative 5-year incidence of brain metastases amounted to 18.9% (when PCI was 
administered) and 45.9% (when PCI was omitted) and these differences were significant (p < 0.0001). PCI was an inde-
pendent prognostic factor for BMFS and for OS. Omitted PCI is related with HR amounted: 6.25 for BMFS and 1.81 for OS.
Conclusions . PCI significantly reduces the incidence of brain metastases and delays the development of brain me-
tastases in patients treated for LD SCLC. PCI is a significant independent prognostic factor for brain metastases-free 
survival and overall survival. The development of brain metastases is the most common type of failure in patients with 
LD SCLC and 90% of such relapses occurred during the 24 months following the completion of chemo-radiotherapy. 
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Introduction
Small-cell lung cancer (SCLC) is an aggressive neuroen-
docrine tumour which accounts for approximately 10–15% 
of all lung cancer cases. This disease is characterised by a 
rapid doubling time and a high degree of sensitivity to 
chemotherapy and radiotherapy. However, this disease has 
widespread metastatic potential [1–4]. Despite these facts, 
at the time of diagnosis only 30–40% of patients with SCLC 
can be classified as having the limited stage of the disease 
(LD SCLC) [5]. According to the Veterans Administration 
Lung Cancer Study Group Classification, limited stage SCLC 
is defined as being confined to one hemithorax and regional 
lymphatic nodes (mediastinum, homolateral and contrala-
teral hilar regions, homolateral supraclavicular fossa) and 
theoretically responsive to radiotherapy. Though limited 
stage SCLC corresponds to stages I–III according to TNM 
classification, but some studies assessed treatment moda-
lities have used the classical not the TNM classification [6–8].
The standard treatment for patients with LD SCLC is 
combined modality therapy that includes chemotherapy 
(ChT) with platinum-based regimens and thoracic radiothe-
rapy (RT), followed by prophylactic cranial irradiation (PCI) 
in patients with a response in the thorax [2, 5, 8–10]. The 
results of randomised trials and meta-analyses showed that 
combined chemo-radiotherapy (ChT-RT) improved tumour 
control as well as overall survival (+5.4% at 2-years) [11, 12]. 
This benefit is observed when ChT-RT is applied as a concur-
rent modality. The results of meta-analyses showed a 5.4% 
absolute increase in the 2-year survival rate for concurrent 
ChT-RT and this effect is particularly evident when thoracic 
RT is administered immediately after the first or second cycle 
of ChT [2, 5, 10, 13–18].
Although SCLC responds to ChT-RT, which results in 
a lower risk of thoracic relapse, the most frequent site of 
disease progression is the brain. The cumulative incidence 
of brain metastases is higher than 50% at 2 years after dia-
gnosis [19–21]. The results of clinical trials and meta-analyses 
showed that PCI diminish the incidence of brain metastases 
and this translates into a 5.4% increase in the 3-year overall 
survival rate [8, 19, 22–24]. Therefore, PCI remains the stan-
dard therapy for all patients with SCLC in whom a response 
to ChT-RT was observed.
The objective of the present study was to evaluate the 
effectiveness of PCI in patients with LD SCLC treated at a sin-
gle centre and to analyse the effects of certain therapeutic 
factors (particular PCI) on the frequency and occurrence of 
brain metastases.
Materials and methods
Between 2002 and 2015, a total of 271 patients with 
LD SCLC received combined treatment (chemotherapy and 
thoracic radiotherapy) at the Maria Skłodowska-Curie Insti-
tute — Oncology Center (MSCI) in Kraków, Poland. 
In our study LD SCLC was defined as a disease limited to 
the hemithorax and ipsilateral supraclavicular lymph nodes. 
The stage of the disease was determined on the basis of the 
patient’s medical history, a physical examination, a patholo-
gy review, computed tomography (CT) of the chest, upper 
abdomen and brain, a magnetic resonance (MR) of the brain, 
chest radiography, laboratory tests and an evaluation of 
pulmonary, cardiac and renal function tests.
Patients and therapeutic methods 
The clinical and therapeutic characteristics of 271 pa-
tients with LD SCLC as whole group and according to ap-
plication of prophylactic cranial irradiation (PCI) are shown 
in Table I.
The mean age of our patients was 60.5 years (ranging 
from 32 to 79 years), and the performance status of 167 
patients (62%) was evaluated as 1 according to the WHO 
scale. The majority of patients (64.2%) were males. 
All patients received chemotherapy according to a PE 
(cisplatin 30 mg/m2 intravenously and etoposide 120 mg/
m2 intravenously) schedule. The chemotherapy consisted 
of 4–6 cycles administered every 3–4 weeks; and 92.6% of 
the patients received 4 or more cycles of PE. 
Thoracic radiotherapy was administered concurrently 
(122 patients — 45% of the total) with RT beginning to 
be administered during ChT, immediately after the first or 
second cycle of PE (106 patients — 86.9%) or after the third 
cycle (16 patients — 13.1%). The remaining 149 patients 
(55% of all) received thoracic radiotherapy on a sequential 
basis (i.e. after the completion of the chemotherapy). Radio-
therapy was applied using a photon beam (6 MV or 18 MV) 
produced in a linear accelerator and a three-dimensional 
treatment planning system was adapted to the conformal 
radiotherapy technique. The gross tumour volume (GTV) 
was defined on the basis of CT scans and included primary 
tumour and involved lymph nodes. The clinical target vo-
lume (CTV) in the first phase included GTV and mediastinal 
and hilar lymph nodes as elective irradiated nodes, whereas 
in the second phase it covered GTV with adequate margins 
(8 mm added isotropically). The planning target volume 
(PTV) in both phases covered the CTV with margins: 7 mm 
axially and 12 mm longitudinally were added to account 
for tumour motion. The total dose administered ranged 
between 40 and 66 Gy (the fractional dose was 1.8–2.0 Gy) 
and amounted on average to 54.2 Gy (median: 54 Gy), and 
the majority of the patients (233 out of 271 — 86%) received 
a dose equal to or greater than 54 Gy. 
Prophylactic cranial irradiation (PCI) was delivered to 
167 patients (61.6%) as “late” PCI (when it was administered 
after ChT-RT; in 86 patients — 51.1%) or “early” PCI (when 
it was administered immediately after the end of thoracic 
irradiation; in 81 patients — 48.9%). During PCI, a total dose 
of 30 Gy in 2-Gy fractions was delivered to the whole brain. 
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The significant differences (Tab. I) between the group 
that received PCI and the group that omitted PCI concerned 
the mean age, the schedule of ChT-RT and the beginning of 
thoracic RT in relation to chemotherapy. The patients who 
received PCI in comparison to whom omitted PCI: (a) were 
significant (p < 0.05) younger (mean age: 58.8 vs 63.3), (b) 
most of them received concurrent ChT-RT (59.9% vs 21.2%), 
and (c) more frequent thoracic RT began earlier — imme-
diately after the first or second cycle of PE (55.1% vs 13.5%).
The response of all the patients to treatment was evalu-
ated 6–8 weeks after the completion of therapy and it was 
assessed on the basis of a chest CT. During the follow-up a 
physical examination was performed every 2 months for the 
first 24 months and every 3 months thereafter. A radiological 
examination (a chest CT and a brain MR) was performed to 
assess the chest (every 6 months) and the brain (every 12 
months or when clinical symptoms are present).
Statistical methods
The results were evaluated as 5-year overall and brain 
metastasis-free survival rates. The survival rates were estima-
ted using the Kaplan-Meier method. The influence of various 
parameters on survival rates was assessed using the log-rank 
test, as well as Cox’s proportional hazards regression model 
to identify independent prognostic factors. The groups were 
compared using Pearson’s chi2 test for independence (for 
categorized variables) and variance analysis based on the 
Student’s t-test (for continuous variables). 
All the calculations were performed using Statistica v. 
13.3 software (TIBCO Software Inc.) and the significance level 
for all the statistical methods was p < 0.05.
Results
Following treatment, complete response (CR) to thoracic 
disease was observed in 172 patients out of a total of 271 
(63.5%), while the remaining 99 patients (36.5%) developed 
partial response (PR). The follow-up period ranged from 3 to 
183 months with a mean of 33.2 months. During this period, 
220 patients (81.2%) died. The causes of death were as fol-
lows: progression of small-cell lung cancer in the thorax (88 
pts; 40%), the development of distant metastases (77 pts; 
35%), and coexistent diseases (17 pts; 7.7%). In the rema-
ining 34 patients (15.5%) the cause of death was unknown. 
During the follow-up period, 84 patients (32.7%) deve-
loped failure in the thorax: recurrence (41 patients out of a 
total of 172 with CR, 23.8%) or progression (43 patients out of 
Table I . The characteristics of 271 patients with LD SCLC in relation to application of prophylactic cranial irradiation (PCI)
Parameters Whole group PCI — yes PCI — no p-value
N = 271
(100%)
% N = 167
(61.6%)
%* N = 104
(38.4%)
%*
Age (in years) range
mean ± SD
median
32–79
60.5 ± 9.1
60.0
32–79
58.8 ± 8.9
59.0
35–79
63.3 ± 8.7
63.5
0.0001a
Gender male
female
174
97
64.2
35.8
103
64
61.7
38.3
71
33
68.3
31.7
0.2709b
Primary tumour localization at side left
right
123
148
45.4
54.6
72
95
43.1
56.9
51
53
49.0
51.
0.3408b
Positive of supraclavicular nodes 14 5.2 11 6.6 3 2.9 0.1806b
Performance status (WHO scale) 1
2
168
103
62.0
38.0
107
60
64.1
35.9
61
43
58.7
41.4
0.3716b
Chemo-radiotherapy (ChT-RT) concurrent
sequential
122
149
45.0
55.0
100
67
59.9
40.1
22
82
21.2
78.9
0.0000b
ChT–number of PE cycles range
mean ± SD
median
1–6
4.9 ± 0.9
5.0
2–6
4.9 ± 0.8
5.0
1–6
4.9 ± 1.1
5.0
0.8140a
4–6
1–3
251
20
92.6
7.4
157
9
94.6
5.4
94
10
90.4
9.6
0.1898b
Thoracic RT after PE cycle 1 or 2
3 or more
106
165
39.1
60.9
92
75
55.1
44.9
14
90
13.5
86.5
0.0000b
Thoracic RT– dose (in Gy) range
mean ± SD
median
40–66
54.2 ± 3.9
54.0
40–66
54.3 ± 3.2
54.0
40–60
53.8 ± 4.8
54.0
0.2084a
PCI (yes) early
late
81
86
48.5
51.5
ChT-RT — chemoradiotherapy, ChT — chemotherapy, PE — cisplatin and etoposide, PCI — prophylactic cranial irradiation, SD — standard deviation, *percentage in 
relation to subgroup, aVariance analysis (Student t-test), bchi2 test 
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a total of 99 with PR — 43.4%). The mean time it took for the 
above thoracic failures to develop was 17.2 months in the 
case of recurrence and 5.4 months in the case of progression. 
Distant metastases occurred in 120 patients (44.3%), 
and the mean time of this type of failure was 8.2 months. 
The most common location of distant failure was the brain 
(61 pts, 50.8%), where metastases developed after a mean 
time of 11.4 months following ChT-RT (range: 1–96 months). 
Other locations of distant metastases were as follows: lymph 
nodes (36 pts, 30%), liver (19 pts, 15.8%), bones (16 pts, 
13.3%), suprarenal glands (9 pts, 7.5%), lungs (8 pts 6.7%), 
pancreas (2 pts, 1.7%), and the skin (1 pt, 0.8%). 
The 5-year overall (OS) and brain metastases-free (BMFS) 
survival rates were 23% and 60.3%, respectively.
Figure 1 shows the probability of (a, c) overall survival 
and (b, d) brain metastasis-free survival both for the whole 
group (a, b) as well as in relation to the administration of 
PCI (c, d).
The cumulative 5-year incidence of brain metastases in 
relation to PCI amounted to 18.9% (when PCI was admini-
stered) and 45.9% (when PCI was omitted). This difference 
was statistical significant (p = 0.0000, log-rank test).
The results of the multivariate Cox’ proportional hazard mo-
del showed that one statistically significant independent factor 
affecting survival rates (OS and BMFS) was the administration 
of prophylactic cranial irradiation (Tab. II). The risk increased 
when PCI was omitted: brain metastases-free survival (HR = 
6.25, p = 0.0000), and overall survival (HR = 1.81, p = 0.0000). 
The role of the administration of PCI was also evident 
when evaluating the frequency of brain metastases in rela-
tion to time intervals following ChT-RT (Fig. 2). The majority 
of the brain metastases (90.2%) occurred within twenty-four 
months of treatment. A significant correlation was observed 
between the administration of PCI and the reduction rate 
(11.4% vs 40.4%, p = 0.0000, chi2 test) and occurrence delay 
(27.6 vs 4.0 months, p = 0.0017, Student’ t-test) of brain 
metastases compared to when PCI was not administered. 
The influence of certain therapeutic factors on the fre-
quency and timing of the brain metastases is summarized 
in Table III, and Figure 3 shows the probability of brain meta-
a b
c d
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Figure 1 . The probability of (a, c) overall survival and (b, d) brain metastasis-free survival in the whole group (a, b) as well as in relation to the 
administration of PCI (c, d)
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Table II . The results of multivariate proportional hazard Cox’ model
Parameter HR 95% CI p-value
Overall survival
PCI: no vs yes 1.81 1.36–2.40 0.0000
response: PR vs CR 2.50 1.86–3.37 0.0000
Brain metastases-free survival
PCI: no vs yes 6.25 3.59–10.87 0.00000
HR — hazard ratio, CI — confidence interval, PCI — prophylactic cranial irradiation, PR — partial response, CR — complete response
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Figure 2 . The frequency of brain metastases in time intervals following chemo-radiotherapy (ChT-RT) in relation to application of prophylactic 
cranial irradiation (PCI)
Table III . The influence of PCI and other therapeutic factors and treatment results for frequency and time of brain metastases occurrence in patients 
with LD SCLC
Features Brain metastases p-value
chi2 test
Time period between ChT-
RT and occurrence of brain 
metastases
(mean ± SD)
p-value
Student’s t-testyes 
N = 61 (22.5%)
no 
N = 210 (77.5%)
No of pts. % No of pts. %
ChT-RT concurrent
sequential
18
43
14.8
28.9
104
106
85.3
71.1 0.0057
34.5 ± 40.9
19.9 ± 26.8 0.0008
RT after PE cycle 1 or 2
3 or more
15
46
14.2
27.9
91
119
85.9
72.1 0.0083
23.9 ± 25.8
7.3 ± 14.4 0.0027
Response in chest CR
PR
37
24
21.5
24.2
135
75
78.5
75.8 0.6043
15.8 ± 23.2
4.6 ± 4.2 0.0067
PCI yes
no
19
42
11.4
40.4
148
62
88.6
59.6 0.0000
27.6 ± 27.8
4.0 ± 3.6 0.0017
PCI (yes) early
late
10
9
12.4
10.5
71
77
87.7
89.5 0.7021
38.4 ± 44.1
31 ± 29.2 0.4970
ChT-RT — chemoradiotherapy, RT — radiotherapy, PE — cisplatin and etoposide, CR — complete regression, PR — partial regression, PCI — prophylactic cranial 
irradiation, SD — standard deviation
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stases-free survival (BMFS) curves in relation to: (a) schedule 
of chemo-radiotherapy: concurrent vs sequential, (b) begin-
ning of thoracic radiotherapy: after 1st or 2nd cycle vs 3rd 
cycle chemotherapy, (c) response to treatment: complete 
vs partial, and (d) time of PCI application: “early” vs “late”. 
The brain metastases were rare and developed later 
when: (a) ChT-RT was performed concurrently, (b) thoracic 
RT commenced immediately after the 1st or 2nd cycle of 
PE (early thoracic RT), and when (c) prophylactic cranial 
irradiation was used, and these differences were significant. 
Furthermore, the achievement of complete response after 
ChT-RT was associated with a delay in brain metastases 
compared with patients with partial response (15.8 vs 4.6 
months, p = 0.0017). On the other hand, despite the signi-
ficant role of prophylactic cranial irradiation, the timing of 
PCI (“early” or “late” PCI) did not have major influence on the 
frequency and occurrence of brain metastases.
The 5-year brain metastases-free survival (BMFS) 
rates were as follows: 60.3% (for the group as a whole), 
81.1% vs 50.5% (respectively, for PCI vs no PCI, p = 0.0000, 
log-rank test), 76.4% vs 64% (concurrent vs sequential 
ChT-RT, p = 0,0006, log-rank test), 76.2% vs 65.7% (thoracic 
RT after 1 or 2 cycles of ChT vs after 3 or more cycles of ChT, 
p = 0.0011, log-rank test). Significant differences in BMFS 
were also observed in relation to the post ChT-RT response; 
the 5-year rates were 72.9% and 66.2%, respectively, for CR 
and PR (p = 0.0338, log-rank test).
Discussion
Brain metastases (BM) are the most common form of 
SCLC relapse. The 2-year cumulative risk of brain metastases 
is higher than 50% in patients with LD SCLC [19–21].
In the case of our material, brain metastases developed 
in 61 (22.5%) out of a total of 271 patients with LD SCLC. 
Papers published in 2017 presented similar results. Accor-
ding to data from Wu et al. [25] and Farooqi et al., [26] brain 
metastases were observed in 19% and 21.1% of all cases, 
respectively.
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Figure 3 . The probability of brain metastases-free survival (BMFS) in relation to: (a) schedule of chemo-radiotherapy: concurrent vs sequential, 
(b) beginning of thoracic radiotherapy: after 1st or 2nd cycle vs later, (c) response to treatment: complete vs partial, and (d) time of PCI application: 
“early” vs “late”
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The efficacy of combined (ChT-RT) treatment reduces 
the risk of thoracic failure and brain metastases become 
the main type of relapse. The hypothesis that the brain is a 
pharmacological sanctuary for microscopic tumours against 
systemic chemotherapy suggests that prophylactic cranial 
irradiation may be considered as a strategy for eradicating 
non-detectable brain metastases. This treatment method 
has been shown to reduce the incidence of brain metasta-
ses and to help improve the survival rate. The role of PCI in 
reducing brain metastases has been assessed extensively in 
patients with LD SCLC. The results of clinical trials and meta-
-analyses showed that PCI not only significantly decreases 
the incidence of brain metastases, but also results in higher 
overall survival rates [23, 24, 27, 28]. Auperin’s meta-analysis 
showed that PCI reduces the risk of brain metastases (from 
59% to 33% at 3 years) and at the same time improves the 
3-year survival rate (a 5.4% gain for overall survival and an 
8.8% gain for disease-free survival) [23]. Similar observations 
reported by other authors confirmed the significant role 
played by the administration of PCI in decreasing (an ave-
rage of 14–36%) the incidence of brain metastases [22, 27, 
29–31]. Patel et al. [24] performed a retrospective analysis of 
7995 patients and showed that PCI is a significant predictor 
of survival; the 5-year survival rate was 19% when PCI was 
administered compared with 11% when PCI was omitted. 
Our observation confirmed the significant benefits of 
administering PCI. Brain metastases developed in 11.4% 
of patients who received PCI as compared with 40.4% of 
patients when PCI was omitted. Moreover, we observed 
that brain metastases developed significantly later in pa-
tients with PCI compared with cases in which no PCI was 
administered (mean time: 27.6 vs 4.0 months, respectively; 
p = 0.0017, Student’s t-test). Another benefit of PCI was an 
improvement in survival rates; the 5-year overall survival ra-
tes were as follows: 32.4% (with PCI) and 8.4% (without PCI) 
and this difference was significant (p = 0.0000, log-rank test).
Farooqi et al. [26] observed that the administration of 
PCI was associated with a significantly lower frequency and 
delayed occurrence of brain metastases compared with 
cases that did not involve PCI (frequency: 18.1% vs 24.8%, 
mean time of occurrence: 16.8 vs 8.2 months, respectively). 
Instead, Tai et al. [32] showed that PCI significantly delayed 
the mean time at which brain metastases occurred (20.7 
vs 10.6 months in cases with or without PCI, respectively).
The administration of PCI was an independent progno-
stic factor affecting survival rates both in the case of brain 
metastases-free survival and overall survival [25, 26, 29]. 
We showed that the hazard ratios for cases where PCI was 
omitted were 6.25 for brain metastases-free survival and 
1.81 for overall survival. A similar observation presented 
Eze et al. [29] who showed that patients without PCI had 
poorer overall survival — the hazard ratio in their multiva-
riate analysis averaged 1.899. The recently published results 
of other authors confirmed that the administration of PCI 
not only significantly decreases the risk of brain metastases, 
but also it is an independent significant factor for survival 
rates [25, 26]. 
Another analysis of the effectiveness of PCI concerned 
the total dose and time of delivery. The results of an EORTC 
phase 3 randomized trial comparing the effect of standard 
versus higher PCI doses on the incidence of brain metastases 
showed that there was an insignificant reduction in the total 
incidence of brain metastases after a high dose of PCI and the-
re was also a significant increase in mortality [33]. On the other 
hand, the early administration of PCI was based on Auperin’s 
clinical observations and theoretical conditions (Suwinski’s 
group) that revealed an almost linear dose-response rela-
tionship in relation to a reduction in brain metastases which 
is evidence in favour of early PCI application [23, 34, 35]. Our 
previous observation confirmed that early administered PCI 
(immediately after the completion of thoracic radiotherapy) 
lowered the incidence of brain metastases compared with 
the later application of PCI (7.3% vs 20% respectively for 
early vs late PCI) [36]. Unfortunately, our present results did 
not confirm what influence the timing of PCI delivery has on 
the development of brain metastases. It is conspicuous that 
the current group in comparison to early presented group is 
nearly twice as large (271 vs 129 cases) and the mean time 
of the follow-up is longer (33 vs 19 months). 
Restricting PCI carries the risk of the development of 
neurotoxicity. According to data from the literature, neu-
rotoxicity affects 10–70% of patients treated for SCLC. The 
most common neurological dysfunctions include cognitive 
impairment and memory problems [37–39]. It is important 
to note that these neuropsychological problems may not 
only be a consequence of PCI, but might also result from 
the cancer itself and the anticancer therapy. Therefore, in 
patients with LD SCLC the earliest possible administration 
of chemotherapy in combination with chest radiotherapy 
should be considered the standard treatment, followed by 
prophylactic cranial irradiation for patients with tumour 
response and no contraindications for this procedure. 
Conclusions
1. Prophylactic cranial irradiation (PCI) significantly redu-
ces the incidence of brain metastases and delays the 
development of brain metastases in patients treated 
for LD SCLC. The cumulative 5-year incidence of brain 
metastases amounted to 18.9% (when PCI was admini-
stered) and 45.9% (when PCI was omitted).
2. Prophylactic cranial irradiation is a significant indepen-
dent prognostic factor for brain metastases-free survi-
val (BMFS) and overall survival (OS). The relative risk of 
omitting PCI amounted 6.25 for BMFS and 1.81 for OS.
3. The development of brain metastases is the most com-
mon type of failure in patients with LD SCLC and 90% of 
287
such relapses occurred during the 24 months following 
the completion of chemo-radiotherapy. In the case of 
the present group, brain metastases affected 22% of 
all patients and 51% of all cases involving distant me-
tastases. 
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